Jump to the top of the page

Showing 620 – 630 of 1297 results

  • Ken Langston

    View biography for Ken Langston, Partner, Managing Director, Private Wealth Management Branch Leadership.

  • 2025 Wealth Planning and Philanthropy Strategies

    Last year’s election results have set the stage for significant changes in tax legislation. We explore several strategies you might consider to help you meet your financial, wealth-transfer, and philanthropic goals.

  • The Quarterly Rx Q1 2023 US Biopharma Recap

    The year kicked off with renewed optimism for the biopharma sector, but “macro” concerns resurfaced to end the quarter.

  • The Quarterly Rx Q2 2023 US Biopharma Recap

    Biopharma markets closed the first half of 2023 with renewed optimism and an encouraging outlook for the rest of the year.

  • Cybersecurity 2020 Trust No One Verify Everyone

    The term zero trust has become the next in a long line of popular terms used by cybersecurity companies to associate their offerings with a more sophisticated, next-generation approach.

  • Ellen Blair Chube Receives Emerging Philanthropist Award

    Ellen-Blair Chube, a William Blair partner and a managing director with the firm’s investment banking team, received the emerging philanthropist award from the Association of Fundraising Professionals (AFP) in Chicago at its annual gala.

  • Hamilton Lane Incorporated Initiation

    William Blair & Company initiated research coverage of Hamilton Lane Incorporated (HLNE $67.26), one of the world’s leading allocators of capital to the private markets, including private equity, real estate, credit, and real assets.

  • iRhythm Technologies Inc Initiation

    William Blair & Company initiated research coverage of iRhythm Technologies, Inc. (IRTC $71.50), a digital health company that provides solutions designed for diagnosing cardiac arrhythmias.

  • Thryv Holdings Inc Initiation

    William Blair & Company initiated research coverage of Thryv Holdings, Inc. (THRY $10.04). Thryv helps small and local businesses get discovered by customers.

  • Silence Therapeutics plc

    William Blair & Company initiated research coverage of Silence Therapeutics plc (SLN $15.50), a clinical-stage biopharmaceutical company focused on developing proprietary GalNAc-conjugated siRNA therapeutics for genetically defined life-threatening disorders.

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures